Summit Therapeutics Closes $2B Equity Investment From AstraZeneca
Summit Therapeutics Inc. has closed a $2.0 billion equity investment from AstraZeneca, structured as preferred stock convertible into common stock at an implied price of $18.36 per share. The funding will support the development of ivonescimab.
36 per share. The investment is intended to fund development of ivonescimab.